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Abstract
 .  .The b-amyloid peptide A b or A4 is produced by proteolytic cleavage from amyloid precursor protein APP . The
progressive cerebral deposition of this peptide is one of the most important features of Alzheimer’s disease. From the study
of normal and transfected cells, two APP processing pathways have been proposed as physiological alternatives. One of
these can produce A b or amyloidogenic peptides, whereas the second does not. However, it is not completely clear how
APPs are post-translationally modified, proteolytically processed and metabolized in the brain. We report here that APPs
 .also exist as proteoglycan, chondroitin-sulfate ChS . We have identified in normal rat brain a complex pool of 8 to 130
 .kDa ChS-core proteins. The main portion of these proteoglycan PGs APPs contains complete amyloidogenic sequence,
suggesting a novel proteolytic processing of APP from the amino-terminal to the transmembrane region. This population
appears augmented after brain damage. These findings may have significant implications in understanding the initial
deposition and kinetics of amyloid aggregation in a pathological situation like Alzheimer’s disease. q 1998 Elsevier Science
B.V. All rights reserved.
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1. Introduction
One of the most important features of Alzheimer’s
disease is the progressive cerebral deposition of b-
 .amyloid peptide A b , either in blood vessels or
w x around neurites 1,2 . This A b or A b4 peptide 4
.kDa, 40–42 aa is proteolytically derived from a
transmembrane protein denoted amyloid precursor
 . w xprotein APP 3–6 . Using normal and transfected
cells, two APP processing pathways have been pro-
posed as physiological alternatives. One of them, the
‘conventional’ secretory processing pathway, pre-
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cludes the generation of the A b. In this pathway an
 .undefined protease activity alpha-secretase cleaves
w xb-amyloid precursor at amino acid 16 of A b 7–9 .
This pathway produces secreted forms of APP, such
 .as the Kunitz protease inhibitor KPI -containing-APP
w xknown as nexin II 10–12 . Alternatively, a minority
of APPs could be processed by a different pathway,
the ‘amyloidogenic’ pathway. This has to be initiated
 .by the activity of a different protease b-secretase
that would lead to the formation of C-terminal frag-
ments containing the complete A b sequence for
w x.review see Ref. 13 .
The fact that A b can be produced by cultured
cells, of either neuronal or non-neuronal lineages
w x14–16 , provides a powerful model system for ana-
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lyzing the molecular mechanisms leading to A b for-
mation in cells. However, it is not clear how APPs
are post-translationally modified, processed and me-
tabolized in brain. Moreover, we have little informa-
tion regarding the biochemical nature of the different
APP molecular species existing in a normal brain.
A family of integral membrane proteins are in-
cluded under the name of APP. At least eight differ-
ent forms of APP are now known, and they are
obtained by alternative splicing from a single gene
w x w x.17 , for review see Ref. 18 . These proteins are
post-translationally modified by proteolytic process-
ing, phosphorylation and glycosylation, including
w xboth N- and O-linked glycosylation 19 . In fact,
glycosylation seems to be a prerequisite for secretion
w x20 . Large glycosylated secreted APP derivatives are
present in human cerebrospinal fluid, brain, and in
cell culture medium, perhaps playing a modulatory
w xrole in cell adhesion 21–23 .
The presence of putative proteoglycan glycosyla-
tion sites within the APP sequence support the sug-
gestion that this protein may also be a proteoglycan
 .PG . Data obtained from the soluble fraction of
neural cells and established cell lines supported this
w xnotion 24–26 but more recently it was shown that
 .APP without exon 15 denoted by L-APP may be a
w xchondroitin-sulfate type PG 23,27–29 .
The aim of this work was to determine if APPs
exist as proteoglycans in adult rat brain and how this
specific glycosylation could be modified after brain
injury. To this end, we have purified and character-
 .ized the APP-proteoglycan fraction APP-PG from
control and damaged adult rat brains.
We report here that in adult rat brain, there exists
an APP proteoglycan population of the chondroitin-
 .sulfate type ChS . We have identified a complex set
of 8 to 130 kDa ChS-core proteins. The majority of
these proteoglycan derivatives correspond to APP
peptides although some of these may correspond to
APP homologues. Interestingly, the main portion of
these ChS peptides contain the complete A b se-
quence, and are thus potentially amyloidogenic frag-
ments. Our quantitative data shows that even though
part of the purified PGs may correspond to APP-ho-
mologues, the total amount of PG-APP is not a minor
population with respect to the N- and O-glycosylated
APP previously reported. The same number of ChS-
APP core proteins were detected in both injured and
control brains, but quantitative differences were de-
tected.
Considering the high aggregation capacity shown
by APP andror A b with proteoglycans, these find-
ings may have significant implications for under-
standing amyloid deposition and its initial aggrega-
tion steps in Alzheimer’s disease.
2. Material and methods
2.1. Surgical procedure
 .Adult male Wistar rats 200–250 g were anes-
thetized with sodium pentobarbital Nembutal, Abbot
.Laboratories; 50 mgrkg . Isomorphic lesion was in-
flicted on a group of rats by unilateral intraventricular
 . injections of a solution of kainic acid Sigma 0.75
. .  .mg ns18 or with a solution of AMPA Sigma
 .  . 9.5 mg ns18 , in phosphate buffer 0.1 M, pH
.  .7.2 PB . Injections were made over 10 min, using a
5 ml Hamilton syringe, using the following stereo-
taxic coordinates: nose bar, q5; on bregma 1.5 ML
w xand 4.7 DV 30 . Under these conditions, different
areas of the ipsilateral hippocampus Kainic acid
.affected the CA3–4 and AMPA the area CA1 were
affected. Whereas the controlateral hippocampus was
w xnot directly affected 31,32 .
2.2. Plasma membrane purification
Ipsilateral brain or undamaged rat brain were ob-
tained after 12 days post-lesion. Brain tissue was
 .homogenized in cold HEPES buffer 20 mM, pH 7.2
in an Ultra-Turrax T25 homogenizer Janke and
.Kunkel , at 20 000 rpm. Homogenate was centrifuged
at 600=g for 15 min, and the supernatant cen-
trifuged at 50 000=g for 45 min, at 48C. The pellet
 .P2 was resuspended in the same buffer and overlay-
ered on a gradient composed of 0.8, 1, 1.3 M sucrose
 .in HEPES buffer 20 mM, pH 7.2 . Centrifugation at
50 000=g for 60 min allowed the complete separa-
tion of plasma membranes, recovered at the interface
w xbetween 0.8r1 M and 1r1.3 M sucrose 33 . All the
steps were carried out in the presence of protease
 .  .inhibitors, aprotinin 1 mgrml , leupeptin 1 mgrml ,
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 .PNGB 1 mgrml and phenylmethylsulfonide
 .  .PMSF 0.1 mM .
2.3. PGs purification
Proteoglycans were obtained from different mem-
branes of total adult rat brain and hippocampi. Pro-
teoglycan fractions were obtained by anion-exchange
chromatography on DEAE-cellulose DE-52, What-
.man . For this purpose, membrane fractions from
different tissues were homogenized in cold 20 mM
 .HEPES pH 7.2 with 7 M Urea Buffer A , containing
0.4% Triton-X100, protease inhibitors; maintained
for 10 min at 48C, and centrifuged 100 000=g, 1 h,
.48C .
Alternatively, total brain was directly homoge-
nized as above, to minimize ‘post-mortem delay’.
Solubilized extract was pooled on a DEAE-Cellulose
column equilibrated in buffer A and, after washing
with buffer A plus 0.2 M NaCl, proteoglycans were
eluted in buffer A plus 1 M NaCl. The 1 M NaCl
fraction was extensively dialyzed in 5 mM HEPES
and lyophilized. All the steps were carried out in the
 .presence of protease inhibitors, aprotinin 1 mgrml ,
 .  .leupeptin 1 mgrml , PNGB 1 mgrml and phenyl-
 .  . w xmethylsulfonide PMSF 0.1 mM 2 .
The protein concentration was determined by two
different methods, absorbance and colorimetric deter-
 .  .mination Bradford using BSA 1 mgrml as a
control.
2.4. Antibodies
Polyclonal antisera were prepared against putative
antigenic peptides of the b-amyloid precursor pro-
 .teins APPs , corresponding to residues 322 to 336 of
751  .APP P1 , and against regions of the b-amyloid
 .  .peptide A4 , corresponding to residues 1 to 12 P4
 .and 27 to 40 P5 . They were produced by intrader-
mal injections into rabbits of the synthetic peptides
 .coupled to keyhole limpet hemocyanin KLH or
BSA. The IgG fraction was affinity purified using
Protein A-Sepharose. The purified IgGs were pre-ab-
sorbed with the corresponding carrier protein BSA
.or KLH , titred and used between 35–50 mgrml
w x34,35 . In Western-blots these antibodies recognize a
group of proteins between 110 to 130 kDa in normal
w xbrain 35 .
A commercial polyclonal antisera against b-
 . amyloid, A b 4 Alz. peptide a1381 431,
.Boehringer, Mannheim , was compared with our anti-
bodies. This antisera and anti-P1 were immobilized
 .into Protein A-Sepharose Pharmacia , to prepare
affinity chromatography columns, as described be-
low.
Antisera against the carboxy-terminal portion of
APPs were kindly supplied by Dr. F. Mayor Menedez,
 .UAM-CBM, Spain a675 , raised against amino acids
675 to 695 APP695; and a589 against amino acids
y8 to q10 aa considering the first amino acid of
.A b peptide to be q1 and Dr. Greg M. Cole,
UCLA, USA a681, against amino acids 681 to 695
695.of APP .
A commercial polyclonal antiserum against anti-
 .D-xylose aCH11-503, Cambridge Res. Biochem.
was used in Western-blots, diluted 1r100. The im-
munoreactivity shown by this antibody aCH11-503
 .anti-Xyl. was blocked by pre-incubation of the di-
 .luted antibody with D-xylose 70 mM but not with
 .lactose or glucose 100 mM .
In Western-blots, all of these antisera were incu-
bated for 4 h at 378C. After rinsing the membrane
three times with 0.150 M NaClr50 mM Tris, pH 7.5,
 .0.2% Tween-20 TBS-T , they were incubated with
alkaline-phosphatase conjugated anti-rabbit Pro-
.mega , for 2 h at room temperature. After washing,
the immunoreactivity was visualized with a solution
w xof NBT-BCIP 36 .
2.5. PG-APP purification
PG-APP was purified from a total proteoglycan
fraction by affinity chromatography. The IgG fraction
 .from the polyclonal antiserum P1 against the Kunitz
domain was immobilized on a Protein A-Sepharose
column by standard procedures using dimethylpimed-
w ximilate as cross-linker 36 . The affinity column was
equilibrated in 20 mM HEPES, pH 7.2, 0.1 M NaCl,
0.5 mM EDTA, and the PG fraction was passed
 .through the column slowly 1 mlr3 min . After
washing with 3 volumes of equilibrating buffer and 2
volumes of 5 mM HEPES, APP-PG was eluted with
0.2 M acetic acid and the pH of the sample was
buffered with the lowest amount of ammonium hy-
 .droxide 0.5 M , to a pH of 7–7.5. Finally, APP-PG
fractions were lyophilized. Alternatively, PG-APP
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was purified as described above, but using the anti-
 .body against b-amyloid, Alz. peptide a1381 431 ,
 .Boehringer, Mannheim immobilized in an affinity
chromatography column.
2.6. SDS-PAGE and immunoblotting
 .Similar amounts of PG-APP 2–5 mg were treated
 .with the glycosidase chondroitinase ABC 0.5 Urml
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 .  .andror heparinases I 0.5 Urml , II 0.1 Urml and
 .  .III 0.05 Urml all from Sigma in the presence of
50 mgrml of BSA and protease inhibitors 1 mM
.PMSF and 1 mg rml of leupeptine , for 5 h at 378C.
The maximal digestion was empirically determined
by taking samples from the digestion at 2, 4 and 6 h.
During this time no proteolytic activity was observed.
The digested samples were separated by SDS-PAGE
under reducing conditions, using 9% separating gels
w x37 or by Tricine–SDS-PAGE in 16.5%:3% gels
w x38 . After electrophoresis, proteins were transferred
to a nitrocellulose membrane which was then blocked
with 5% non-fat dry milk in 0.15 M NaClr50 mM
 .Tris, pH 7.5r0.2% Tween-20 TBS-T overnight.
Specific anti-APP antibodies or antisera were used as
 .  .follows: anti-A b 1–40 Boehringer IgG 10–20
mgrml; IgGs from anti-P1, anti-P4 and anti-P5 were
used 25–50 mgrml; and antisera a675, a589 and
a681, all were diluted 1r500 in TBS-T.
2.7. Dot-blot analysis and densitometric determina-
tions
PG-APP purified by affinity chromatography was
quantified by dot-blot with the antibodies anti-P4 and
anti-P1, using the purified recombinant protein mal-
APP751 as a control. The recombinant APP751 in the
 .p-mal-p2 cloning vector New England Biolabs was
kindly provided by Dr. Cristina Haas, from Dr. F.
 .Valdivieso Lab. CBM-UAM, Madrid .
To quantify the APP-PG purified, increasing
amounts of APP-PG and mal-APP751 were dotted
onto nitrocellulose membrane. After blocking with
5% non-fat dry milk in TBS-T, the membrane was
incubated with either anti-P4 or anti P-5, as previ-
ously described. Densitometric analysis was per-
formed on four different dot-blots. They were incu-
 .bated with two different antisera anti-P4 and anti-P5
and processed with an Imaging densitometer GS-
.6470 model, Biorad . The data were analyzed with
the Molecular Analyst software.
3. Results
3.1. Antibody characterization
In order to characterize the APP fractions purified
from adult brain we developed a series of polyclonal
antibodies to synthetic peptides from different re-
 . gions of APP Fig. 1A . These peptides P1, P4 and
.P5 were coupled to BSA or KLH and injected in
different rabbits. From the different antisera obtained
we purified the IgG fraction which were pre-absorbed
with the corresponding ‘carrier’ protein.
The specificity of these IgGs were demonstrated
 .because all of them anti-P1, P4 and P5 recognized
not only the original peptides but also the purified
bacterial hybrid protein mal-APP751 whereas they did
not recognize the bacterial extract obtained from
 .  .control expression vector alone p-mal Fig. 1B .
Additionally, these purified IgGs recognized a protein
of 110–120 kDa from adult rat brain membrane and
 . 751Fig. 1. Characterization of APP antibodies. A Schematic structure of APP . TM, represents the transmembrane region; KPI designates
 .the Kunitz protease inhibitor domain and A b the amyloid peptide. Horizontal bars indicate the antigen synthetic peptides for the
 751.  .  .  . different antibodies: P1 322–336 APP ; P4 1–12 A b ; P5 27–40 A b ; P6 25–35 A b , anti-A4 1–40 from Boehringer,
.  .Mannheim ; and 675 and 589 kindly supplied by Dr. F. Mayor Menendez, 681 kindly supplied by Dr. Greg Cole. B Extracts from
751 751  .bacteria expressing p-mal alone, or expressing p-mal-APP and purified p-mal-APP fusion protein lanes 1, 2, and 3, respectively
 .were electrophoretically separated and stained with Coomassie C or transferred to nitrocellulose filters. Identical blots were incubated
 .with the purified IgGs from anti-P1, P4 and P5. In similar blots with only lanes 2 and 3 the immunoreactivity was blocked by
pre-incubation of the diluted antibodies with the purified recombinant APP751. The molecular weight standards are listed in kilodaltons.
 .  .C Identical amounts of membrane from control rat brain Brain Mem. were electrophoretically separated and the Western-blots analyzed
with the purified IgGs from the different APP antisera. The arrow-head represents the position of the recombinant protein APP751 which
has an apparent molecular weight of 130 kDa and the arrow indicates the position of high molecular weight APPs. Identical amounts of
 .cell extract from type-I astrocytes Astr. were electrophoretically separated and the Western-blots analyzed with antibody against anti-P4.
 .The immunoreactivity indicates the presence of two high molecular weight components arrow-heads that correspond with APPs. This
positive immunoreaction was blocked by pre-incubation of the diluted antibody with the purified recombinant mal-APP751. The molecular
weight standards are listed in kilodaltons.
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two proteins of 120–130 kDa from astrocyte mem-
 .branes Fig. 1C .
Both immunoreactivities were abolished by the
pre-incubation of these antibodies with the purified
protein mal-APP751.
3.2. APP-PG purification and characterization
The presence of consensus sequences for different
glycosylation sites in the APP amino acid sequence
opens up the possibility that APP exists as proteogly-
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 .can PG in rat brain. Soluble forms of PG-APPs
w xhave been previously described in cell lines 24–26
and indeed, it has recently been shown that APP
corresponding to the protein lacking exon 15, known
as L-APP may be a chondroitin-sulfate type PG
w x27–29 . To investigate whether similarly glycosy-
lated APPs were present in rat brain, we purified the
PGs fraction from rat brains and examined the effects
of glycosidase digestion on APP immunoreactivity.
Membrane fractions from adult rat brains and hip-
pocampus were obtained as described above. The
total proteoglycan fraction was solubilized from these
membranes, using a solution containing Triton X-100
and chaotropic solvents such as urea. PG were recov-
 .ered by ion-exchange chromatography DEAE , in
the presence of high concentrations of urea and were
eluted from this column at a high salt concentration.
From the total PG population, the putative APP-pro-
teoglycan fraction was selected by affinity chro-
matography column which was prepared by immobi-
lizing IgGs from a polyclonal antiserum against the
 .  .Kunitz domain of APP P1 Fig. 1A .
The immunopurified PG-APP were electrophoreti-
cally separated and analyzed by Western-blots, fol-
lowing digestion with or without chondroitinase ABC.
After this treatment different APP core proteins were
 .detected Fig. 2A .
To characterize these APP-core proteins, we used
polyclonal antibodies that recognized different APP
 .regions Fig. 1A . Several of these antibodies recog-
nized a similar subset of high molecular weight pep-
 .tides in Western-blots Fig. 2A .
Antibodies raised against peptides P1 Kunitz re-
. gion , and P4 and P5 the amino and carboxy-termi-
.nal regions of A b showed different populations of
APP existing as PGs. After chondroitinase ABC di-
gestion, antibody against P1 showed a wide range of
APP derivatives from 130 to 30 kDa. No peptides
were observed without GAG-degrading enzymes ad-
 .dition or the enzyme mixture alone Fig. 2A . Inter-
estingly, the majority of these P1-immunopositive
peptides, were P4-positive proteins and were also
bound specifically by polyclonal antibody anti-P5
 .Fig. 2A that recognizes the complementary car-
 .boxy-terminal region of A b4 28–40 aa . No prote-
olytic activity was detected even after 6 h of treat-
 .ment with glycosidases Fig. 2B . The double diges-
tion heparinases I, II and III and chondroitinase
.ABC revealed a minor population composed of two
peptides of 90 kDa and 40 kDa and a minor band of
 .120 kDa arrowheads in Fig. 2 .
The analysis of similarly digested samples in
Tris–Tricine SDS-PAGE gels revealed the presence
of low molecular weight peptides in the chondroiti-
nase digestion but not in the heparinase digested
samples. In Western-blots, the antibody against P4
recognized a 17 kDa peptide, while the antibody
anti-P5, also detected two additional peptides of 25
 .and 8 kDa Fig. 2C . All peptides recognized by P4
 .  .and P5 high and low molecular weight Fig. 2A
were also labeled by commercially available anti-A b
 .  .myloid antibody A b , Boehringer Data not shown
 .and with polyclonal antisera 589 Data not shown .
Moreover, we obtained identical results with these
antibodies when a commercial antibody against A b
was used to purify PG-APPs by affinity chromatogra-
 .phy Data not shown .
In order to complete the structural characterization
of PG-APP, we tried to define the extent of the
carboxy-terminal region of these core proteins. For
 .Fig. 2. Analysis of PG-APPs after glycosidase digestion. A The PG-APPs were purified by affinity chromatography using the antibody
 .against P1. From this purified PG-APP, similar amounts 2–5 mg were electrophoretically resolved after glycosidase digestion. Ch
 .  .represents digestion with chondroitinase ABC Sigma ; ChqHp is the double digestion, heparinase I, II and III Sigma plus
 .chondroitinase. y Represents the undigested fraction. Ch.ABC represent the mixture reaction without the addition of PG-APP. The
Western-blots were incubated with the antibodies against P1, P4, P5 and 675. The molecular weight standards are listed in kilodaltons.
 .B Similar amounts of PG-APP were electrophoretically resolved in a 10% SDS-PAGE gel, after 6 h of glycosidase digestion. The gel,
 .stained with Coomassie, shows no degradation on BSA after this treatment. The molecular weight standards are listed in kilodaltons. C
Similar amounts of purified PG-APP were electrophoretically separated in Tris–Tricine 16.5%:3% gels, after chondroitinase ABC
 .  .digestion, as in A . Nitrocellulose sheets were incubated with antipeptides P4, P5 and 675. Ch.ABC represents the fraction containing
the enzyme mixture alone, and anti-P5qAPP751 represent preincubation of the anti-P5 with the recombinant protein mal-APP751. The
molecular weight standards are listed in kilodaltons.
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this purpose we used the polyclonal antisera 675 and
681. The majority of the PG-APP-core proteins rec-
ognized by P4 and P5 were labeled by both antisera
 .Fig. 2A and C , suggesting that PG-APP core-pro-
teins contain the cytoplasmic terminal APP domain.
The existence of several proteins that co-purify
with brain PGs and which dissociate under reducing
w xconditions has been reported 39 . In our experiments
none of these APP derivatives were resolved without
previous digestion with GAG-degrading enzymes,
even though we included saturating concentrations of
urea, and boiled the samples in SDS-buffer.
However, in order to demonstrate that these pro-
teins recognized in Western-blot are authentic PG
.Fig. 3. A Schematic representation of a prototypic glycosaminoglycan chain in a protein. Glycosaminoglycan chains are initiated at a
 .serine residue at least in chondroitin, dermatan and heparan sulfate proteoglycans by the addition of xylose and two galactose residues.
 .  .After these, the combination of repeated dimers formed by uronic acid GlU.A glucuronic or iduronic and n-acetyl-galactosamine or
 .  .N-acetyl glusosamine G-NAc , with different sulfation levels s gives rise to the structural differences of heparan, chondroitin or
 .  .dermatan. Hp.ase and Ch.ase, represent the location of the last digested dimer by heparinases or chondroitinases. B and C PG-APP
 .  .  .Western-blot with the antibody against poly-D-xylose. B Purified 3 mg PG-APP was digested with chondroitinase Ch , and separated
in a 9% SDS-PAGE gel. Following transfer to nitrocellulose, the filter was incubated with the antibody against D-xylose. Ch.ABC
 .represent the mixture reaction without the addition of PG-APP. C Similar amounts of digested PG-APP were separated in Tris–Tricine
gels to analyze low molecular weight peptides and the Western-blot incubated with the anti-Xylose antibody. Ch.ABC represent the
mixture reaction without the addition of PG-APP. The immunoreactivity was inhibited almost completely, by pre-incubation with the
 . .  .  .monosaccharide D-xylose 70 mM qXyl. , but not when glucose or lactose 100 Mm was included with anti-xylose antibody C . The
high and low molecular weight standards are listed in kilodaltons.
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core proteins and not high affinity PG associated
proteins, we have used a commercial antibody against
D-xylose. Xylose monosaccharide is the first sugar in
the glycosaminoglycans at least in dermatan, chon-
.droitin and heparan-sulfate types covalently bound
to serine which remains associated with the protein
core following glycosidase digestion see diagram,
.Fig. 3A .
After digestion with GAG-degrading enzymes, the
main APP-core proteins, ChS-APP, were labeled by
this antibody, including those of lower molecular
 .weight Fig. 3B and C . This immunoreactivity was
 .competed by D-xylose 70 mM but not by glucose or
 .  .lactose 0.1 M Fig. 3C . These results confirm the
identity of these APP derivatives as PGs.
Finally, we have quantified the total PG and PG-
APP content in normal brains by two independent
methods. From three independent purifications, we
determined the amount of total PGS obtained which
 .  .was 1.55 "0.15 mgrg tissue Table 1 . From these
total PGS, the amount of PG-APP purified was quan-
tified by Bradford assay which was 70 mg "5rg,
considering three independent purifications. When we
processed the soluble protein fraction, usually dis-
carded in membrane purification, we detected a
smaller amount of PG-APP approximately ten times
Fig. 4. Analysis of PG-APPs after glycosidase digestion from damaged and controls brains. The PG-APPs were purified by affinity
 .  .chromatography using the antibody against P1. Similar amounts 2–5 mg of purified PG-APP from damaged K. Br. and controls brains
 .  .C. Br. were electrophoretically resolved after glycosidase digestion. Ch represents digestion with chondroitinase ABC Sigma ; ChqHp
 .is the double digestion, heparinase I, II and III Sigma plus chondroitinase. The Western-blots were incubated with the antibody against,
 .P5. The molecular weight standards are listed in kilodaltons. A Similar amounts of PG-APP were electrophoretically resolved in a 10%
 .SDS-PAGE gel, after 6 h of glycosidase digestion. The molecular weight standards are listed in kilodaltons. y Represents the
 .  .  .undigested fraction. B Similar amounts of purified PG-APP from damaged K. and controls brains C. were electrophoretically
 .  .  .separated in Tris–Tricine 16.5%:3% gels, after the double digestion, heparinase I, II and III Sigma plus chondroitinase ChqHp . y
Represents the undigested fraction. Ch.ABC represent the mixture reaction without the addition of PG-APP. Nitrocellulose sheets were
 .incubated with either antipeptides P5 or P4 Data not shown . The molecular weight standards are listed in kilodaltons.
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Table 1
 .APP-PG quantification from rat brain ns3
mg PGrg PG-APPsrg PG-APPsrPGs
tissue tissue mg
 .1.55 mg 70 mg "5% 45 mg
 .) 60–65 mg
Quantification of PG-APPs purified from rat brain.
From the same amount of rat brain, we followed the purification
steps of PG-APPs, using identical procedures and chromatogra-
phy columns. The total PG fraction was estimated in both cases
and the PG-APPs obtained by affinity chromatography refer to
the tissue weight or total PGs fraction. The amount of protein
was estimated by Bradford assay and represents the average of
three independent purifications.
 .The asterisk ) indicates the amount of immunoreactive APP-PG
determined by dot-blot analysis using increasing amounts of
purified mal-APP751 as positive control. This determination was
realized with antibodies anti-P4 and anti-P5.
.less . To determine the amount of APP more pre-
cisely we developed a semi-quantitative dot-blot
analysis, using the purified mal-APP751 as a positive
control. These blots were probed with anti-P4 and
anti-P5. From these blots the amount of immunoreac-
tive APP-PG calculated from brain tissue was 60–65
mgrg.
3.3. Differences in PG-APP populations from brain
damage and control brains
For this work we have obtained and separately
processed rat brain samples after 12 days post-lesion.
We purified the total proteoglycan fraction and the
PG-APP with the same procedures.
Identical amount of proteins were digested with
GAG-degrading enzymes and Western-blots were an-
alyzed with the same antibody dilution of two anti-
 .bodies anti-P4 and anti-P5 , and from these
Western-blots no qualitative differences were ob-
served. The same number of ChS-APP’s core-pro-
teins were detected in both injured and control brains,
but clear quantitative differences were detected. Some
specific bands of both high and low molecular weight
appeared more intense in the brain damaged samples
 .Fig. 4 . We quantified these differences by densito-
metric measurements of different blots 16 different
.lanes from eight different blots , disregarding the 25
kDa and 8 kDa peptides. This analysis showed a
 .significant increase 32"5% of PG-APP in dam-
aged brains with respect to the control brains.
4. Discussion
The principal aim of this work was to purify and
characterize the APP-PG present in rat brain. For this
purpose we developed a series of polyclonal antibod-
ies against different APP region, using synthetic pep-
tides coupled to carrier proteins. The selected regions
 .were located in the Kunitz inhibitory sequence P1
 .and in the A b region P4, and P5 . It should be
noted that the P1 sequence is present not only in APP
but also in the APP homologues APLP 1 and APLP
. w x2 40,41 whereas the P4 sequence is only present in
w xAPP 40 .
The specificity of these antibodies was demon-
strated with the bacterial purified protein p-mal
APP751 which was recognized by all purified IgGs
from anti-P1, P4 and P5. These antibodies recognized
a band of 110–120 kDa in rat brain membranes and a
band of 120–130 kDa in primary type-I astrocytes.
This immunoreactivity was abolished by the presence
of purified mal-APP751 which confirms that these
proteins correspond to either full-length or proteoti-
cally processed APP. Identical results were obtained
with the commercially available antibody against A b
peptide.
After obtaining these antibodies, we purified and
characterized the PG-APP fraction present in adult
brain. The presence of putative PG glycosylation sites
GSG or XSG in the APP sequence opens up the
possibility that APP may exist as a proteoglycan.
These consensus sequences are located at positions
 .  .  .56 PSG , 590 GSG and 603 DSG , relative to the
695 w xAPP sequence 6 . This modification has been
demonstrated, at least in cell culture, for the L-APP
w xwhich are those isoforms without exon 15 28–30 .
Our data show that in adult rat brain there is a
population of PG-APP, which is mainly composed of
the chondroitin-sulfate type.
The population of APP-ChS contained a wide
range of core proteins, with molecular weights rang-
ing from 130 kDa to 8 kDa. The proteins with
molecular weights from 130 to 96 may correspond to
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the full length APPs because they are P4-positive and
 .contain the KPI-region P1-positive from carboxy-
 .terminal region 675 and 681-positives . The lower
molecular weight peptides mainly correspond to frag-
ments of APP extending from the transmembrane
region to the cytoplasmic tail, as indicated by the
positive reaction with antibodies against the A b pep-
 . tide P4 and P5 and carboxy-terminal region 675 or
.681 .
The comparison between the double-digestion
with both glycosidases heparinase and chondroiti-
.nase and chondroitinase alone, showed the presence
of a second population doubly-glycosilated ChS and
.HpS . This population is composed of two main
peptides of 90 and 40 kDa and a minor component of
130 kDa. We cannot rule out the possibility that this
component will be APP or a new APP homologue
which co-purified with our PG-APP fraction. A more
detailed study will be performed in order to study this
matter.
The characterization of all these core proteins with
 .different APP antibodies P4, P5, 675 and 681
showed that the majority of APP-ChS contain the
complete A b region, except for the 25 and 8 kDa
peptides. Similar results were obtained when PG-APP
was purified using commercial anti-A b antibody in
the affinity column. Furthermore, most of the anti-P1
positive bands were also recognized by anti-P4 and
P5 antibodies which specifically bind to amyloido-
genic sequences. In fact, the P4 sequence is exclu-
sively present in APP, which strongly supports the
hypothesis that P4-positive and P5-positive peptides
correspond to APP peptides and not to APP homo-
logues. Only a minority of KPI-positive bands were
not recognized by these antibodies, which opens up
the possibility that these peptides correspond to
amino-terminal fragments of APP or some KPI-con-
w xtaining APP homologue protein 40 .
The 25 kDa peptide, despite its higher molecular
weight, is also P5-positive but P4-negative; and 675-
positive but 681-negative. We propose that this pep-
tide is derived from an APP homologue, containing
chondroitin-sulfate, that co-purifies with APP. The
significance of this is not clear and must be analyzed
in more detail. In fact, from the two APP homologues
described so far, only the APLP2 has been reported
w xto contain chondroitin-sulfate 28–30,40 and the
amino acid sequence of this protein presents homolo-
gies with APP in the P5 and 675 regions, but does
not contain the P4 sequence. The 8 kDa peptide could
correspond to a fragment of APP carboxy-terminal
since it was recognized by the antibody P5. However,
it does not contain the amino-terminal region as
defined by P4 immunoreactivity. This suggests that
this peptide could correspond either to the APP car-
boxy-terminal region or to a similar fragment from an
APP homologue, such as the 25 kDa peptide.
An important consideration is that we obtained the
same pattern of APP and peptides independently of
whether we used anti-P1 or anti-A b. Most of these
peptides contain the complete A b region but not all
contain the complete KPI region. Thus, we have to
assume that not all PGs that we obtained with anti-P1
column were purified by criteria of ‘affinity’. We
have to admit that we purified complex APP-PG
KPI-containing fractions and APP-PG peptides stabi-
lized by either proteinrglycosaminoglycan or glyco-
saminoglycanrglycosaminoglycan interactions. In-
deed, PGs have been shown to bind the A b peptide
w x42,43 . We cannot distinguish whether these com-
plexes are relevant in vivo or were formed during the
purification process.
Previous reports have demonstrated that some neu-
ral cells and established cell lines can secrete APP
w xcontaining ChS 25–28 . Nevertheless, we have to
consider the possibility that some of the proposed
APP core proteins in rat brain are in fact PG-binding
proteins. This possibility appears to be unlikely be-
cause no core proteins were resolved without previ-
ous digestion with GAG-degrading enzymes in strong
denaturing conditions including saturating urea and
after boiling the samples in reducing electrophoretic
.buffer .
In order to demonstrate the authenticity of these
PG core proteins, we used a commercial antibody
against D-xylose. This monosaccharide is present in
PGs covalently bound to serine dermatan, chon-
.droitin and heparan-sulfate types and is retained
after glycosidase digestion. Our data clearly show
that the main APP-core proteins were recognized by
this antibody, and this immunoreactivity was almost
completely abolished by competition with 70 mM
D-xylose. Thus, we conclude that these APP core
proteins exist as authentic PGs in rat brain. Support-
ing the results we present here, it has recently been
demonstrated that the APP isoform lacking exon 15
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 .L-APP can be modified as a chondroitin-sulfate
w xtype, at least in cell culture 29,30 .
We found a strong correlation among APP-PG
core-protein patterns, independently of the membrane
source used which suggests that they are not pro-
duced during the purification process, post-mortem
delay or digestion with GAG-degrading enzymes. All
steps included different protease inhibitors, and in the
case of the treatment with GAG-degrading enzymes
we added BSA which was never proteolytically de-
graded. In fact, we have obtained PG-APP fractions
from human brains where the PG-APP pattern was
qualitatively similar to those already described O.
.Salinero and F. Wandosell, submitted .
Additionally, the core proteins described corre-
spond to peptides from the amino-terminal to the
carboxy-terminal region of APP. We never detected
the complementary peptides amino-terminal peptides
.without carboxy-terminal region which cannot corre-
spond to ‘accidental’ proteolysis. In fact, identical
mixture of GAG-degrading enzymes and anti-pro-
tease compounds were used with other proteoglycans
w xand we did not detect any proteolytic activity 32 .
All these data strongly suggest that the addition of
glycosaminoglycan chain to APP modify the accessi-
bility to the ‘secretases’ action, implying the exis-
tence of a new processing pathway for APP. In this
hypothetical new pathway, contrary to those de-
scribed for the NrO-glycosylated APP population,
the proteolytic processing could be initiated from the
amino-terminal portion of the precursor protein, gen-
erating a ‘complex pool’ of carboxy-terminal deriva-
tives, those which are a new source of amyloidogenic
fragments in brain tissue.
Whether the core-proteins of these APP-PG popu-
lations correspond exclusively or not to isoform L-
APP remains to be investigated but we postulate that
they correspond to L-APP with or without the KPI-
insert.
Another important observation from our results is
that the PG-APP population is an important compo-
nent of the total APP present in the mammalian brain.
Our quantitative data from total brain show that the
amount of PG-APP purified is around 70 mg"5rg
tissue, while using a semi-quantitative dot-blot we
obtained 60–65 mgrg. The amount purified from
brain reported for the APP N- and O-glycosylated
 .non-proteoglycan and non-glycosylated population
w xis 46 mgrg 23 . Even considering the possibility that
part of the total PG-APP corresponds to APP-related
proteins, this PG-APP population appears to be an
important fraction of the total APP present in the
brain. This novel route could complete the potential
of APP for posttranslational processing, and serve as
an alternate source of amyloidogenic fragments.
The second aim of this work was to determine
whether this specific glycosylation could be modified
after brain injury. To this end, we used a model of
hippocampal injury following kainic acid treatment
w x31,34 and from these brains we purified the corre-
sponding fraction of APP-proteoglycan. We analyzed
this purified fraction with the antibodies previously
described and no qualitative differences were ob-
served. The same number of ChS-APP’s core-pro-
teins were detected in both injured and control brains,
but clear quantitative differences were detected. The
densitometric analysis showed an important increase
 .32"5% of PG-APP in damaged brains with re-
spect to the control brains. If we consider that L-APP
is the only form of PG-APP and that this isoform is
w xmainly, if not exclusively, present in glial cells 26
we could suggest that the reactive glia would be the
cellular source of this APP population.
This new APP population may be relevant in brain
metabolism for many reasons. First, because this
would represent part of a ‘positive’ glial response
after injury of the affected neurons. Second, because
this mainly contains the complete A b sequence,
these PG-APP are located in the plasma membrane
and appear to form complexes with glycosaminogly-
cans. PGs, in particular of the HpS type, have been
w xshown to bind the A b peptide 42,43 and it has been
postulated that some PGs could facilitate A b aggre-
w xgation 44 . In support of this hypothesis, it has
recently been demonstrated that continuous infusion
 .in rat brain of A b plus an Hs-PG Perlecan leads to
w xfibrillar amyloid deposit formation 45 . We should
consider the possibility that this new PG-APP popula-
tion could interact with other PGs, such as Perlecan,
increasing the condensation capacity of A b , perhaps
acting over and above the initial kinetics of amyloid
aggregation, or as nucleating factors. In fact, accumu-
lation of PGs occurs in parallel with amyloid deposi-
w xtion 44,46 . Since APP-ChS derivatives are poten-
tially amyloidogenic, this could reveal the initial
elements involved in amyloid deposition.
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